179 related articles for article (PubMed ID: 18307561)
1. Thalidomide in advanced mastocytosis.
Damaj G; Bernit E; Ghez D; Claisse JF; Schleinitz N; Harlé JR; Canioni D; Hermine O
Br J Haematol; 2008 Apr; 141(2):249-53. PubMed ID: 18307561
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
Gruson B; Lortholary O; Canioni D; Chandesris O; Lanternier F; Bruneau J; Grosbois B; Livideanu C; Larroche C; Durieu I; Barete S; Sevestre H; Diouf M; Chaby G; Marolleau JP; Dubreuil P; Hermine O; Damaj G
Br J Haematol; 2013 May; 161(3):434-42. PubMed ID: 23432617
[TBL] [Abstract][Full Text] [Related]
3. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.
Simon J; Lortholary O; Caillat-Vigneron N; Raphaël M; Martin A; Brière J; Barète S; Hermine O; Casassus P;
Pathol Biol (Paris); 2004 Jun; 52(5):294-9. PubMed ID: 15217717
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide therapy in systemic mastocytosis.
Kluin-Nelemans HC; Ferenc V; van Doormaal JJ; van Iperen C; Peters WG; Akin C; Valent P
Leuk Res; 2009 Mar; 33(3):e19-22. PubMed ID: 18644623
[No Abstract] [Full Text] [Related]
5. [Refractory anaemia successfully treated with thalidomide].
Hansen M; Hansen PB
Ugeskr Laeger; 2006 Feb; 168(6):591-2. PubMed ID: 16476224
[TBL] [Abstract][Full Text] [Related]
6. CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis.
Hollmann TJ; Brenn T; Hornick JL
Am J Surg Pathol; 2008 Jan; 32(1):139-45. PubMed ID: 18162781
[TBL] [Abstract][Full Text] [Related]
7. Systemic mastocytosis: current concepts and treatment advances.
Tefferi A; Pardanani A
Curr Hematol Rep; 2004 May; 3(3):197-202. PubMed ID: 15087068
[TBL] [Abstract][Full Text] [Related]
8. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
[TBL] [Abstract][Full Text] [Related]
9. Two cases of concomitant acquired aplastic anemia and systemic mastocytosis.
Golardi N; Sramek JE; Myers JB; Saffer H; George TI; Czuchlewski DR
Hum Pathol; 2014 Feb; 45(2):417-20. PubMed ID: 24182560
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case.
Butterfield JH; Tefferi A; Kozuh GF
Leuk Res; 2005 Feb; 29(2):131-4. PubMed ID: 15607359
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone.
Ramasamy K; Lim Z; Pagliuca A; Salisbury JR; Mufti GJ; Devereux S
Haematologica; 2006 Aug; 91(8 Suppl):ECR44. PubMed ID: 16923528
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
13. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma.
Kim Y; Weiss LM; Chen YY; Pullarkat V
Leuk Res; 2007 Dec; 31(12):1749-54. PubMed ID: 17544505
[TBL] [Abstract][Full Text] [Related]
14. Systemic mastocytosis mimicking inflammatory bowel disease: A case report and discussion of gastrointestinal pathology in systemic mastocytosis.
Bedeir A; Jukic DM; Wang L; Mullady DK; Regueiro M; Krasinskas AM
Am J Surg Pathol; 2006 Nov; 30(11):1478-82. PubMed ID: 17063092
[TBL] [Abstract][Full Text] [Related]
15. Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease.
Hauswirth AW; Födinger M; Fritz M; Müllauer L; Simonitsch-Klupp I; Streubel B; Chott A; Sperr WR; Jäger U; Valent P
Hum Pathol; 2008 Jun; 39(6):917-24. PubMed ID: 18448146
[TBL] [Abstract][Full Text] [Related]
16. [Systemic mastocytosis].
Fain O; Stirnemann J; Lortholary O
Rev Prat; 2005 Oct; 55(15):1629-36. PubMed ID: 16334197
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis.
Elliott MA; Pardanani A; Li CY; Tefferi A
Leukemia; 2004 May; 18(5):1027-9. PubMed ID: 15014525
[No Abstract] [Full Text] [Related]
18. Thalidomide: mechanisms of action.
Paravar T; Lee DJ
Int Rev Immunol; 2008; 27(3):111-35. PubMed ID: 18437602
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance.
Böhm A; Födinger M; Wimazal F; Haas OA; Mayerhofer M; Sperr WR; Esterbauer H; Valent P
J Allergy Clin Immunol; 2007 Jul; 120(1):192-9. PubMed ID: 17451799
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo DJ; George TI; Linder A; Langford C; Perkins C; Ma J; Westervelt P; Merker JD; Berube C; Coutre S; Liedtke M; Medeiros B; Sternberg D; Dutreix C; Ruffie PA; Corless C; Graubert TJ; Gotlib J
Leukemia; 2018 Feb; 32(2):470-478. PubMed ID: 28744009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
